|Bid||0.00 x 0|
|Ask||365.70 x 0|
|Day's range||361.65 - 366.55|
|52-week range||293.05 - 384.20|
|Beta (5Y monthly)||0.28|
|PE ratio (TTM)||22.52|
|Earnings date||03 Feb 2022|
|Forward dividend & yield||9.10 (2.49%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||391.58|
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Anthem, Inc. (ANTM), and Infosys Limited (INFY).
AstraZeneca's (AZN) sBLA seeks approval of Enhertu for unresectable and/or metastatic HER2-positive metastatic breast cancer previously treated with an anti-HER2-based regimen.
Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.